Table 1 Comparison of baseline characteristics between 120 patients with advanced hepatocellular carcinoma who received pembrolizumab or nivolumab
From: Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Characteristics | Pembrolizumab (n = 25) | Nivolumab (n = 95) | P value |
|---|---|---|---|
Age (median, range) | 58 (32–83) years | 61 (38–84) years | 0.42 |
Sex | Â | Â | Â |
 Male | 19 (76.0%) | 75 (78.9%) | 0.75 |
 Female | 6 (24.0%) | 20 (21.1%) |  |
Child–Pugh classification |  |  |  |
 A | 18 (72.0%) | 73 (76.8%) | 0.62 |
 B (7) | 7 (28.0%) | 22 (23.2%) |  |
BCLC classification | Â | Â | Â |
 C | 25 (100%) | 95 (100%) |  |
ALBI grade | Â | Â | Â |
 1 | 7 (28.0%) | 36 (37.9%) | 0.43 |
 2 | 18 (72.0%) | 59 (62.1%) |  |
Hepatitis B | Â | Â | Â |
 Yes | 19 (76.0%) | 61 (64.2%) | 0.27 |
 No | 6 (24.0%) | 34 (35.8%) |  |
Hepatitis C | Â | Â | Â |
 Yes | 7 (28.0%) | 26 (27.4%) | 0.95 |
 No | 18 (72.0%) | 69 (72.6%) |  |
Macrovascular invasion (IVC, HV, PV) | Â | Â | Â |
 Yes | 14 (56.0%) | 50 (52.6%) | 0.76 |
 No | 11 (44.0%) | 45 (47.4%) |  |
Main portal vein thrombosis | Â | Â | Â |
 Yes | 4 (16.0%) | 16 (16.8%) | 0.92 |
 No | 21 (84.0%) | 79 (83.2%) |  |
History of hepatectomy | Â | Â | Â |
 Yes | 11 (44.0%) | 40 (42.1%) | 0.87 |
 No | 14 (56.0%) | 55 (57.9%) |  |
Extrahepatic spread | Â | Â | Â |
 Yes | 18 (72.0%) | 48 (50.5%) | 0.06 |
 No | 7 (28.0%) | 47 (49.5%) |  |
Lymph node metastasis | Â | Â | Â |
 Yes | 7 (28.0%) | 34 (35.8%) | 0.47 |
 No | 18 (72.0%) | 61 (64.2%) |  |
Treatment lines | Â | Â | Â |
 2 | 11 (44.0%) | 55 (57.9%) | 0.21 |
 ≥ 3 | 14 (56.0%) | 40 (42.1%) |  |
AFP (median, range) ng/ml | 1378 (2.6 – > 80,000) | 834 (2.1 – > 80,000) | 0.10 |